Abstract: An isolated monoclonal antibody that specifically binds human Siglec15, or an antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell, and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the same.

Abstract: An isolated monoclonal antibody that specifically binds human C5, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. Further provided are a bispecific molecule, an immunoconjugate, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using an anti-C5 antibody or the antigen-binding portion thereof.

Abstract: An isolated monoclonal antibody that specifically binds human PD-1, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. Further provided is a bispecific molecule and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using the anti-PD-1 antibody or the antigen-binding portion thereof.

Abstract: An isolated monoclonal antibody that specifically binds human Siglec15, or an antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the same.

Abstract: An isolated monoclonal antibody that specifically binds human CTLA4, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. The present disclosure further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using the anti-CTLA4 antibody or the antigen-binding portion thereof.

Abstract: An isolated monoclonal antibody that specifically binds human IL6R, or an antigen-binding portion thereof is provided. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. Further provided is a bispecific molecule, an immunoconjugate, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using an Anti-IL6R antibody or the antigen-binding portion thereof.

Abstract: An isolated monoclonal antibody that specifically binds human Siglec15, or an antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the same.

Abstract: An isolated monoclonal antibody that specifically binds human IL4R?, or an antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. The present disclosure further provides a bispecific molecule, an oncolytic virus and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using an Anti-IL4R? antibody or the antigen-binding portion thereof of the disclosure.

Abstract: An isolated monoclonal antibody that specifically binds human BCMA, or the antigen-binding portion thereof. The present disclosure further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, or an oncolytic virus comprising the antibody or the antigen-binding portion thereof, as well as a nucleic acid molecule encoding the same.

Abstract: An isolated monoclonal antibody that specifically binds human RANKL, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. A treatment method using an anti-RANKL antibody or the antigen-binding portion is provided.

Abstract: The present invention provides an isolated monoclonal antibody, or an antigen-binding portion thereof, specifically binding to CD40. The present invention further provides a pharmaceutical composition comprising the antibody, or the antigen-binding portion thereof, as well as a treatment method using the antibody or the antigen-binding portion thereof, or the pharmaceutical composition.